Published in J Immunol on February 15, 2002
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med (2002) 1.18
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
IFNα Inducible Models of Murine SLE. Front Immunol (2013) 0.97
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms. PLoS One (2013) 0.93
Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol (2004) 0.92
High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS One (2008) 0.92
CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity (2004) 0.92
CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Mol Immunol (2010) 0.87
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity (2016) 0.84
Hormonal milieu at time of B cell activation controls duration of autoantibody response. J Autoimmun (2014) 0.84
Modification of accessory molecule signaling. Springer Semin Immunopathol (2006) 0.84
CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression. Cell Mol Immunol (2013) 0.83
Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 0.82
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther (2014) 0.81
CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol (2011) 0.81
Defects in Germinal Center Selection in SLE. Front Immunol (2015) 0.81
B cells require "nurturing" by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus. Clin Immunol (2010) 0.79
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights (2014) 0.79
TLR7 influences germinal center selection in murine SLE. PLoS One (2015) 0.78
A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia (2014) 0.76
CD275-Independent IL-17-Producing T Follicular Helper-like Cells in Lymphopenic Autoimmune-Prone Mice. J Immunol (2016) 0.76
The effect of BAFF inhibition on autoreactive B cell selection in murine SLE. Mol Med (2016) 0.75
[Pathogenesis of systemic lupus erythematosus]. Z Rheumatol (2015) 0.75
Clinical manifestations and analyses of the cytotoxic T-lymphocyte associated-4 gene in two Japanese families with systemic lupus erythematosus. Clin Exp Nephrol (2008) 0.75
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem (2003) 3.19
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 2.60
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol (2008) 1.79
Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med (2012) 1.63
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum (2008) 1.55
Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol (2014) 1.54
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol (2004) 1.53
Murine tumor necrosis factor α-induced adipose-related protein (tumor necrosis factor α-induced protein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF-κB, STAT-3 signaling, and dysregulated apoptosis of macrophages. Arthritis Rheum (2012) 1.52
Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis (2007) 1.51
BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol (2004) 1.44
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum (2008) 1.43
Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum (2005) 1.41
Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum (2010) 1.37
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem (2005) 1.34
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis (2011) 1.33
Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A (2010) 1.33
Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum (2011) 1.29
A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol (2011) 1.25
Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett (2002) 1.25
Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol (2007) 1.23
Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum (2008) 1.22
Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol (2012) 1.21
Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum (2012) 1.18
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int (2009) 1.13
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum (2002) 1.12
Targeting of the immune system in systemic lupus erythematosus. Expert Rev Mol Med (2008) 1.08
Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. J Immunol (2005) 1.08
Blockade of interleukin-6 signaling suppressed cochlear inflammatory response and improved hearing impairment in noise-damaged mice cochlea. Neurosci Res (2009) 1.07
BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol (2011) 1.06
Inhibition of Helicobacter hepaticus-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. J Immunol (2006) 1.06
Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res (2011) 1.06
Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum (2009) 1.05
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev (2008) 1.03
Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum (2003) 1.00
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull (2008) 0.99
Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine (2012) 0.99
IFNα Inducible Models of Murine SLE. Front Immunol (2013) 0.97
IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int (2009) 0.97
Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int (2009) 0.95
IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine (2010) 0.95
Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol (2008) 0.94
Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PLoS One (2010) 0.94
The Yaa locus and IFN-α fine-tune germinal center B cell selection in murine systemic lupus erythematosus. J Immunol (2012) 0.94
Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci (2003) 0.94
IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol (2011) 0.93
CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity (2004) 0.92
Plasma cells in systemic lupus erythematosus: the long and short of it all. Eur J Immunol (2011) 0.92
B-cell activating factor targeted therapy and lupus. Arthritis Res Ther (2012) 0.92
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord (2009) 0.91
Effects of alfacalcidol on mechanical properties and collagen cross-links of the femoral diaphysis in glucocorticoid-treated rats. Calcif Tissue Int (2011) 0.91
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Representation of ecological systems within the protected areas network of the Continental United States. PLoS One (2013) 0.90
Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol (2008) 0.90
IL-6 plays an essential role in neutrophilia under inflammation. Cytokine (2011) 0.89
Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis (2009) 0.88
High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. Mod Rheumatol (2010) 0.87
Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice. Clin Dev Immunol (2011) 0.87
The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther (2004) 0.87
Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One (2013) 0.87
Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone (2012) 0.86
Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis Rheum (2012) 0.86
Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone (2009) 0.85
Asymmetric light propagation in composition-graded semiconductor nanowires. Sci Rep (2012) 0.85
Wavelength-converted/selective waveguiding based on composition-graded semiconductor nanowires. Nano Lett (2012) 0.85
Blockade of IL-6 and TNF-α inhibited oxLDL-induced production of MCP-1 via scavenger receptor induction. Eur J Pharmacol (2012) 0.85
IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int (2010) 0.84
Autoimmunity stimulated by adoptively transferred dendritic cells is initiated by both alphabeta and gammadelta T cells but does not require MyD88 signaling. J Immunol (2007) 0.83
Brachial plexopathy as a presenting symptom of giant cell arteritis. J Rheumatol (2002) 0.83
Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha. Rheumatol Int (2008) 0.81
Study of the role of epidermal growth factor on lung fluid transport in rabbits with acute lung injury caused by endotoxin. Exp Ther Med (2012) 0.81
Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol (2010) 0.81
Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice. Rheumatol Int (2010) 0.81